Screening and Treatment with Microdoses of Bevacizumab for Retinopathy of Prematurity in Hospital Pedro de Bethancourth Antigua Guatemala.
DOI:
https://doi.org/10.56172/oftalmica.v18i.10Keywords:
Retinopathy of Prematurity, ROP, Childhood blindness, PathologyAbstract
Retinopathy of Prematurity (ROP) is an important cause of childhood blindness in fully industrialized countries since 1942. Little by little, as care services in neonatal units in developing countries have improved , this pathology is more frequent. Variations in oxygen concentrations during the first postnatal weeks have been shown to be detrimental and favor the development of ROP. This contributes to both phases of Retinopathy development.
Downloads
References
Vinekar A, Dogra M, Azad RV, Gilbert C, Gopal L, Trese M. The changing scenario of retinopathy of prematurity in middle and low income countries: Unique solutions for unique problems. Indian J Ophthalmol 2019;67:717-9 https://doi.org/10.4103/ijo.IJO_496_19
Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res2013;74(Suppl 1):35-49 https://doi.org/10.1038/pr.2013.205
Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS2012;16:501-7 https://doi.org/10.1016/j.jaapos.2012.09.004
Guia para la atención integral para la retinopatía del prematuro, Ministerio de Salud y Asistencia Social, Guatemala, octubre 2018.
Zimmermann M, FAng-Sung J, Porras-Jui D, Cotto E, Romero A, Retinopatía del Prematuro en un país en vías de desarrollo. 2009; 83 (6): 323-326.
Sanchez M, Andrews BJ, Karr D, Lansingh V, Withrop KL, The emergence of retinopathy of prematurity in Guatemala. J Pediatr Ophthalmol Strabismus. 2010; 21:47. https://doi.org/10.3928/01913913-20100324-06
Zimmermann M, Rojas M, Galicia I. Caracteristicas de pacientes con retinopatía del prematuro tratado con LASER en el Instituto Guatemalteco De Seguridad Social del 2012 al 2014. Rev Mex Oftalmol. 2017 https://doi.org/10.1016/j.mexoft.2017.02.001
Zimmermann M, Fong-Sung J, Gaete T. Retinopatía del Prematuro en un Hospital Regional de Guatemala. Revista del Colegio de Médicos de Guatemala. 2012; VI (4): 36-40
Burgos V, Del Cid N, Sarti M, Paiz M, Rivas A. Caracterización de la retinopatia del prematuro en el Hospital Nacional de Chimaltenango. Col Med. Guatem 2017; 156 (1): 39-42. https://doi.org/10.36109/rmg.v156i1.53
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-844. [PubMed: 7683111] https://doi.org/10.1038/362841a0
Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995; 92(3):905-909. [PubMed: 7846076] https://doi.org/10.1073/pnas.92.3.905
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012; 367(26):2515-2526. [PubMed: 23268666] https://doi.org/10.1056/NEJMra1208129
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615. https://doi.org/10.1056/NEJMoa1007374
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94. https://doi.org/10.1001/archopht.121.12.1684
Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of pre¬maturity: a multicenter study in Taiwan. Ophthalmology. 2011;118(1):176-183. https://doi.org/10.1016/j.ophtha.2010.04.018
Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with preth¬reshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155(1):150-158. https://doi.org/10.1016/j.ajo.2012.06.010
Harder BC, Schlichtenbrede FC, Von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intracitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error Result. Am J Ophthalmol 2013; 155: 1119-1124. https://doi.org/10.1016/j.ajo.2013.01.014
Azurdia PJ, Squit C. Dosificador para el tratamiento De retinopatia del Prematuro. Tesis de Graduación Universidad Del Valle de Guatemala. 2013
Azurdi PJ, Squit C. Coronado K, Saenz EV. Calculation of the real and efficient bevacizumab dosage for ROP. Scientific poster. Wordl ROP Meeting Cancun 2017.
Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017 Jun 1;135(6):654-656 https://doi.org/10.1001/jamaophthalmol.2017.1055
Wallace DK. Retinopathy of Prematurity: AntiVEGF treatment for ROP: which drug and what dose? J AAPOS. 2016 Dec;20(6):476-478 https://doi.org/10.1016/j.jaapos.2016.08.013
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Manuel López Morales, Erick Vinicio Saenz Morales, Pablo Azurdia, Carlos Esquit, Paola Salgado, Karla Coronado, Cristian Rodríguez, María Teresa Rubio, Karina Hernández, Norma Pacaja, Sonia Gaytan, Miguel Ángel Soto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
